Form 8-K - Current report:
SEC Accession No. 0001193125-25-135033
Filing Date
2025-06-05
Accepted
2025-06-04 17:36:01
Documents
15
Period of Report
2025-06-03
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d936165d8k.htm   iXBRL 8-K 32623
2 EX-1.1 d936165dex11.htm EX-1.1 193961
3 EX-5.1 d936165dex51.htm EX-5.1 67285
7 GRAPHIC g936165page44a.jpg GRAPHIC 1793
  Complete submission text file 0001193125-25-135033.txt   473754

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA mrus-20250603.xsd EX-101.SCH 2840
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE mrus-20250603_lab.xml EX-101.LAB 17166
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mrus-20250603_pre.xml EX-101.PRE 10781
17 EXTRACTED XBRL INSTANCE DOCUMENT d936165d8k_htm.xml XML 3560
Mailing Address YALELAAN 62 3584 CM UTRECHT DE
Business Address YALELAAN 62 3584 CM UTRECHT DE 31 030 253 8800
Merus N.V. (Filer) CIK: 0001651311 (see all company filings)

EIN.: 000000000 | State of Incorp.: P7 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37773 | Film No.: 251024237
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)